InterMune (FRA:IUX) Debt-to-EBITDA : -0.88 (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is InterMune Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

InterMune's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €13.51 Mil. InterMune's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €159.06 Mil. InterMune's annualized EBITDA for the quarter that ended in Jun. 2014 was €-196.27 Mil. InterMune's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2014 was -0.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for InterMune's Debt-to-EBITDA or its related term are showing as below:

FRA:IUX's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Debt-to-EBITDA only.

InterMune Debt-to-EBITDA Historical Data

The historical data trend for InterMune's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Debt-to-EBITDA Chart

InterMune Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.35

0.71

-1.51

-1.24

-1.31

InterMune Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Debt-to-EBITDA	Get a 7-Day Free Trial															-1.11	-1.42	-1.25	-1.34	-0.88

Competitive Comparison of InterMune's Debt-to-EBITDA

For the Biotechnology subindustry, InterMune's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InterMune's Debt-to-EBITDA falls into.

InterMune Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

InterMune's Debt-to-EBITDA for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	193.524)	/	-147.836
	=	-1.31

InterMune's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2014 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.513	+	159.063)	/	-196.268
	=	-0.88

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2014) EBITDA data.

InterMune (FRA:IUX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

InterMune Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InterMune's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune (FRA:IUX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines